A detailed history of Janus Henderson Group PLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 15,031 shares of VERV stock, worth $68,391. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,031
Previous 15,031 -0.0%
Holding current value
$68,391
Previous $73,000 1.37%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $1,218 - $3,274
-256 Reduced 1.67%
15,031 $73,000
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $378 - $628
35 Added 0.23%
15,287 $203,000
Q4 2023

Feb 14, 2024

SELL
$8.84 - $18.7 $238 - $504
-27 Reduced 0.18%
15,252 $212,000
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $274 - $499
24 Added 0.16%
15,279 $202,000
Q2 2023

Aug 14, 2023

SELL
$13.34 - $19.9 $413 - $616
-31 Reduced 0.2%
15,255 $286,000
Q1 2023

May 15, 2023

BUY
$14.3 - $24.01 $218,589 - $367,016
15,286 New
15,286 $220,000
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $113,598 - $301,549
7,268 New
7,268 $250,000
Q2 2022

Aug 15, 2022

SELL
$11.14 - $23.17 $7.69 Million - $16 Million
-690,011 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$20.92 - $39.36 $9.89 Million - $18.6 Million
-472,785 Reduced 40.66%
690,011 $15.7 Million
Q4 2021

Feb 14, 2022

BUY
$31.94 - $54.82 $61,101 - $104,870
1,913 Added 0.16%
1,162,796 $41.2 Million
Q3 2021

Nov 16, 2021

SELL
$46.0 - $73.99 $11.6 Million - $18.7 Million
-252,888 Reduced 17.89%
1,160,883 $52.5 Million
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $45.1 Million - $85.2 Million
1,413,771 New
1,413,771 $79.8 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.